Effect of PA-MSHA vaccine on plasma phospholipids metabolic profiling and the ratio of Th2/Th1 cells within immune organ of mouse IgA nephropathy.
Phospholipids as a class of important constituents in the biomembranes have been paid increasing attention in many fields. IgA nephropathy is now generally known to be the most common form of primary glomerulonephritis in the world. However, phospholipids metabolism in IgA nephropathy was not clear. Until recently, there was no effective treatment available for patients with IgA nephropathy. In this paper, effect of PA-MSHA vaccine on plasma phospholipid metabolic profile of mouse IgA nephropathy was investigated using high performance liquid chromatography/mass spectrometry (HPLC/MS) and principal components analysis (PCA). Female Balb/c mice were divided into four groups: model group, control group, PA-MSHA treatment group and medicine control group (dipyridamole+common threewingnut root). The experimental IgA nephropathy model was established by the immunity combination method of oral BSA and injection of SEB. It was found that combination of LC/MS technology with PCA can be successfully applied to phospholipids profile analysis, clearly classify the model group and normal group, and PA-MSHA treatment group is closer to the normal control group than medicine control group. The result showed that Th(2)/Th(1) (=CD(4)(+)CD(30)(+)/CD(4)(+)CD(30)(-)) of the model group is 20.70+/-3.57, which is significantly higher than that of the control group (1.34+/-0.14) (P<0.001). The Th(2)/Th(1) ratio of the PA-MSHA treatment group and the medicine control group are lower than that of the model group (P<0.01). It is suggested that mouse IgA nephropathy has the phospholipids metabolic abnormality, PA-MSHA vaccine cannot only regulate the abnormal phospholipids metabolism mouse with the IgA nephropathy, but also correct the over unbalance of Th(2)/Th(1) proportion.
Jia
Lewen
L
National Chromatographic R and A Center, Dalian Institute of Chemical Physics, The Chinese Academy of Sciences, Dalian 116023, China.
Wang
Chang
C
Kong
Hongwei
H
Yang
Jun
J
Li
Fanglou
F
Lv
Shen
S
Xu
Guowang
G
D000818:Animals; D001428:Bacterial Vaccines / Q000494:pharmacology* / Q000627:therapeutic use; D002851:Chromatography, High Pressure Liquid / Q000379:methods; D004195:Disease Models, Animal; D004768:Enterotoxins; D005260:Female; D005922:Glomerulonephritis, IGA / Q000097:blood / Q000139:chemically induced / Q000188:drug therapy* / Q000378:metabolism; D016018:Least-Squares Analysis; D050356:Lipid Metabolism / Q000187:drug effects*; D051379:Mice; D008807:Mice, Inbred BALB C; D010743:Phospholipids / Q000097:blood* / Q000378:metabolism; D025341:Principal Component Analysis; D011550:Pseudomonas aeruginosa / Q000276:immunology*; D011897:Random Allocation; D015203:Reproducibility of Results; D012710:Serum Albumin, Bovine; D021241:Spectrometry, Mass, Electrospray Ionization / Q000379:methods; D013154:Spleen / Q000187:drug effects; D053719:Tandem Mass Spectrometry / Q000379:methods; D018417:Th1 Cells / Q000187:drug effects*; D018418:Th2 Cells / Q000187:drug effects*
D001428:Bacterial Vaccines; D004768:Enterotoxins; D010743:Phospholipids; D012710:Serum Albumin, Bovine; C031818:enterotoxin B, staphylococcal